The firm said that it has received approval for a test that combines the Allsheng-developed Auto-Pure 2400 liquid handling platform with Revvity's T-SPOT.TB test.
Diagnostics' Q4 2024 earnings insights, FDA resubmissions, TB & HPV test pipelines, and international market growth plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback